Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Characterizing Pharmacokinetic-Pharmacodynamic Relationships and Efficacy of PI3Kδ Inhibitors in Respiratory Models of TH2 and TH1 Inflammation.

McLeod RL, Gil MA, Chen D, Cabal A, Katz J, Methot J, Woodhouse JD, Dorosh L, Geda P, Mehta K, Cicmil M, Baltus GA, Bass A, Houshyar H, Caniga M, Yu H, Gervais F, Alves S, Shah S.

J Pharmacol Exp Ther. 2019 May;369(2):223-233. doi: 10.1124/jpet.118.252551. Epub 2019 Feb 25.

PMID:
30804001
2.

Toxicologic Pathology Forum*: Opinion on Integrating Innovative Digital Pathology Tools in the Regulatory Framework.

Gauthier BE, Gervais F, Hamm G, O'Shea D, Piton A, Schumacher VL.

Toxicol Pathol. 2019 Jun;47(4):436-443. doi: 10.1177/0192623319827485. Epub 2019 Feb 5.

PMID:
30722763
3.

Intranodal Angiomyomatous Hamartoma in a Cynomolgus Monkey.

Thirion-Delalande C, Gervais F, Palate B, Forster R, Schenka AA.

Toxicol Pathol. 2019 Feb;47(2):190-195. doi: 10.1177/0192623318814711. Epub 2018 Dec 25.

PMID:
30585127
4.

Structural Remodeling of the Human Colonic Mesenchyme in Inflammatory Bowel Disease.

Kinchen J, Chen HH, Parikh K, Antanaviciute A, Jagielowicz M, Fawkner-Corbett D, Ashley N, Cubitt L, Mellado-Gomez E, Attar M, Sharma E, Wills Q, Bowden R, Richter FC, Ahern D, Puri KD, Henault J, Gervais F, Koohy H, Simmons A.

Cell. 2018 Oct 4;175(2):372-386.e17. doi: 10.1016/j.cell.2018.08.067. Epub 2018 Sep 27.

5.

Discovery of MK-8318, a Potent and Selective CRTh2 Receptor Antagonist for the Treatment of Asthma.

Huang X, Brubaker J, Zhou W, Biju PJ, Xiao L, Shao N, Huang Y, Dong L, Liu Z, Bitar R, Buevich A, Jung J, Peterson SL, Butcher JW, Close J, Martinez M, MacCoss RN, Zhang H, Crawford S, McCormick KD, Aslanian R, Nargund R, Correll C, Gervais F, Qiu H, Yang X, Garlisi C, Rindgen D, Maloney KM, Siliphaivanh P, Palani A.

ACS Med Chem Lett. 2018 Jun 23;9(7):679-684. doi: 10.1021/acsmedchemlett.8b00145. eCollection 2018 Jul 12.

6.

OBE022, an Oral and Selective Prostaglandin F2α Receptor Antagonist as an Effective and Safe Modality for the Treatment of Preterm Labor.

Pohl O, Chollet A, Kim SH, Riaposova L, Spézia F, Gervais F, Guillaume P, Lluel P, Méen M, Lemaux F, Terzidou V, Bennett PR, Gotteland JP.

J Pharmacol Exp Ther. 2018 Aug;366(2):349-364. doi: 10.1124/jpet.118.247668. Epub 2018 May 18.

PMID:
29777040
7.

A human relevance investigation of PPARα-mediated key events in the hepatocarcinogenic mode of action of propaquizafop in rats.

Strupp C, Bomann WH, Spézia F, Gervais F, Forster R, Richert L, Singh P.

Regul Toxicol Pharmacol. 2018 Jun;95:348-361. doi: 10.1016/j.yrtph.2018.04.005. Epub 2018 Apr 5.

PMID:
29626562
8.

Pharmacists' interventions on prescription problems in one French community pharmacy: A prospective pilot study.

Castronovo A, Gervais F, Mongaret C, Slimano F.

Ann Pharm Fr. 2018 Jul;76(4):299-305. doi: 10.1016/j.pharma.2018.02.002. Epub 2018 Mar 16.

PMID:
29555106
9.

Comparative analysis of the oral mucosae from rodents and non-rodents: Application to the nonclinical evaluation of sublingual immunotherapy products.

Thirion-Delalande C, Gervais F, Fisch C, Cuiné J, Baron-Bodo V, Moingeon P, Mascarell L.

PLoS One. 2017 Sep 8;12(9):e0183398. doi: 10.1371/journal.pone.0183398. eCollection 2017.

10.

Systematic review of cost-effectiveness analyses for combinations of prevention strategies against human papillomavirus (HPV) infection: a general trend.

Gervais F, Dunton K, Jiang Y, Largeron N.

BMC Public Health. 2017 Mar 28;17(1):283. doi: 10.1186/s12889-017-4076-3. Review.

11.

Prevalence and Risk Factors for Symptoms of Methotrexate Intolerance in Pediatric Inflammatory Bowel Disease.

Dupont-Lucas C, Grandjean-Blanchet C, Leduc B, Tripcovici M, Larocque C, Gervais F, Jantchou P, Amre D, Deslandres C.

Inflamm Bowel Dis. 2017 Feb;23(2):298-303. doi: 10.1097/MIB.0000000000001014.

PMID:
28107279
12.

Identifying Patients at High Risk of Loss of Response to Infliximab Maintenance Therapy in Paediatric Crohn's Disease.

Dupont-Lucas C, Sternszus R, Ezri J, Leibovitch S, Gervais F, Amre D, Deslandres C.

J Crohns Colitis. 2016 Jul;10(7):795-804. doi: 10.1093/ecco-jcc/jjw038. Epub 2016 Jan 28.

PMID:
26822611
13.

A comparative public health and budget impact analysis of pneumococcal vaccines: The French case.

Jiang Y, Gervais F, Gauthier A, Baptiste C, Martinon P, Bresse X.

Hum Vaccin Immunother. 2015;11(9):2188-97. doi: 10.1080/21645515.2015.1011957. Epub 2015 Aug 12.

14.

Carcinogenicity testing of eliglustat in mice and rats.

Dagher R, Watzinger M, Chevalier G, Thirion-Delalande C, Gervais F, Forster R.

Regul Toxicol Pharmacol. 2015 Oct;73(1):401-12. doi: 10.1016/j.yrtph.2015.07.024. Epub 2015 Jul 30.

PMID:
26232705
15.

Development and pharmacological validation of novel methods of B cell activation in rat whole blood.

Shin J, Spatz M, Brandish P, Gervais F, Zhang-Hoover J, Leccese E, Hicks A.

J Pharmacol Toxicol Methods. 2015 Jan-Feb;71:61-7. doi: 10.1016/j.vascn.2014.12.006. Epub 2014 Dec 26.

16.

A comparative public health and budget impact analysis of pneumococcal vaccines. The french case.

Jiang Y, Gervais F, Gauthier A, Baptiste C, Martinon P, Bresse X.

Value Health. 2014 Nov;17(7):A668. doi: 10.1016/j.jval.2014.08.2467. Epub 2014 Oct 26. No abstract available.

17.

Critical Review of Cost-Effectiveness Analyses (CEA) of Prevention Strategies Against Diseases Associated with Human Papillomavirus (HPV) Infection.

Gervais F, Jiang Y, Largeron N, Nikoglou T.

Value Health. 2014 Nov;17(7):A637. doi: 10.1016/j.jval.2014.08.2288. Epub 2014 Oct 26. No abstract available.

18.

Cost of Previously Treated Chronic Lymphocytic Leukemia (CLL) and Indolent Non-Hodgkin's Lymphoma (INHL) in the United Kingdom (UK).

Cognet M, Druais S, Gervais F, Gauthier A, Abrams KR.

Value Health. 2014 Nov;17(7):A549. doi: 10.1016/j.jval.2014.08.1787. Epub 2014 Oct 26. No abstract available.

19.

Anti-inflammatory actions of Chemoattractant Receptor-homologous molecule expressed on Th2 by the antagonist MK-7246 in a novel rat model of Alternaria alternata elicited pulmonary inflammation.

Gil MA, Caniga M, Woodhouse JD, Eckman J, Lee HH, Salmon M, Naber J, Hamilton VT, Sevilla RS, Bettano K, Klappenbach J, Moy L, Correll CC, Gervais FG, Siliphaivanh P, Zhang W, Zhang-Hoover J, McLeod RL, Cicmil M.

Eur J Pharmacol. 2014 Nov 15;743:106-16. doi: 10.1016/j.ejphar.2014.09.021. Epub 2014 Sep 23.

20.

[Hospital pharmacy residency in France in 2014: to a recognition of the specialization?].

Slimano F, Gervais F, Massé C, Langrée B.

Ann Pharm Fr. 2014 Sep;72(5):317-24. doi: 10.1016/j.pharma.2014.02.005. Epub 2014 Mar 31. French.

PMID:
25220227
21.

Development of a Delayed-Type Hypersensitivity (DTH) Model in the Cynomolgus Monkey.

Bouchez C, Gervais F, Fleurance R, Palate B, Legrand JJ, Descotes J.

J Toxicol Pathol. 2012 Jun;25(2):183-8. doi: 10.1293/tox.25.183.

22.

New indole amide derivatives as potent CRTH2 receptor antagonists.

Zaghdane H, Boyd M, Colucci J, Simard D, Berthelette C, Leblanc Y, Wang Z, Houle R, Lévesque JF, Molinaro C, Hamel M, Stocco R, Sawyer N, Sillaots S, Gervais F, Gallant M.

Bioorg Med Chem Lett. 2011 Jun 1;21(11):3471-4. doi: 10.1016/j.bmcl.2011.03.085. Epub 2011 Mar 30.

PMID:
21515053
23.

Azaindoles as potent CRTH2 receptor antagonists.

Simard D, Leblanc Y, Berthelette C, Zaghdane MH, Molinaro C, Wang Z, Gallant M, Lau S, Thao T, Hamel M, Stocco R, Sawyer N, Sillaots S, Gervais F, Houle R, Lévesque JF.

Bioorg Med Chem Lett. 2011 Jan 15;21(2):841-5. doi: 10.1016/j.bmcl.2010.11.084. Epub 2010 Nov 21.

PMID:
21185722
24.

Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases.

Gallant M, Beaulieu C, Berthelette C, Colucci J, Crackower MA, Dalton C, Denis D, Ducharme Y, Friesen RW, Guay D, Gervais FG, Hamel M, Houle R, Krawczyk CM, Kosjek B, Lau S, Leblanc Y, Lee EE, Levesque JF, Mellon C, Molinaro C, Mullet W, O'Neill GP, O'Shea P, Sawyer N, Sillaots S, Simard D, Slipetz D, Stocco R, Sørensen D, Truong VL, Wong E, Wu J, Zaghdane H, Wang Z.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):288-93. doi: 10.1016/j.bmcl.2010.11.015. Epub 2010 Nov 5.

PMID:
21106375
25.

Pharmacological characterization of MK-7246, a potent and selective CRTH2 (chemoattractant receptor-homologous molecule expressed on T-helper type 2 cells) antagonist.

Gervais FG, Sawyer N, Stocco R, Hamel M, Krawczyk C, Sillaots S, Denis D, Wong E, Wang Z, Gallant M, Abraham WM, Slipetz D, Crackower MA, O'Neill GP.

Mol Pharmacol. 2011 Jan;79(1):69-76. doi: 10.1124/mol.110.068585. Epub 2010 Oct 13.

PMID:
20943773
26.

The utility of the minipig as an animal model in regulatory toxicology.

Bode G, Clausing P, Gervais F, Loegsted J, Luft J, Nogues V, Sims J; Steering Group of the RETHINK Project.

J Pharmacol Toxicol Methods. 2010 Nov-Dec;62(3):196-220. doi: 10.1016/j.vascn.2010.05.009. Epub 2010 May 31. Review.

PMID:
20685310
27.

Identification of distinct plasma biomarker signatures in patients with rapid and slow declining forms of COPD.

Devanarayan V, Scholand MB, Hoidal J, Leppert MF, Crackower MA, O'Neill GP, Gervais FG.

COPD. 2010 Feb;7(1):51-8. doi: 10.3109/15412550903499530.

PMID:
20214463
28.

A-site ordering in colossal magnetoresistance manganite La(1-x)Sr(x)MnO3? Molecular dynamics simulations and quantum mechanics calculations.

Jang YH, Gervais F, Lansac Y.

J Chem Phys. 2009 Sep 7;131(9):094503. doi: 10.1063/1.3190533.

PMID:
19739857
29.

Design, synthesis, and evaluation of novel 3-amino-4-hydrazine-cyclobut-3-ene-1,2-diones as potent and selective CXCR2 chemokine receptor antagonists.

Liu S, Liu Y, Wang H, Ding Y, Wu H, Dong J, Wong A, Chen SH, Li G, Chan M, Sawyer N, Gervais FG, Henault M, Kargman S, Bedard LL, Han Y, Friesen R, Lobell RB, Stout DM.

Bioorg Med Chem Lett. 2009 Oct 1;19(19):5741-5. doi: 10.1016/j.bmcl.2009.08.014. Epub 2009 Aug 7.

PMID:
19713110
30.

A detailed field-based evaluation of naphthenic acid mobility in groundwater.

Oiffer AA, Barker JF, Gervais FM, Mayer KU, Ptacek CJ, Rudolph DL.

J Contam Hydrol. 2009 Sep 1;108(3-4):89-106. doi: 10.1016/j.jconhyd.2009.06.003. Epub 2009 Jun 30.

PMID:
19674813
31.

High-sensitivity nanoLC-MS/MS analysis of urinary desmosine and isodesmosine.

Boutin M, Berthelette C, Gervais FG, Scholand MB, Hoidal J, Leppert MF, Bateman KP, Thibault P.

Anal Chem. 2009 Mar 1;81(5):1881-7. doi: 10.1021/ac801745d.

32.

A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease.

Aisen PS, Saumier D, Briand R, Laurin J, Gervais F, Tremblay P, Garceau D.

Neurology. 2006 Nov 28;67(10):1757-63. Epub 2006 Nov 2.

PMID:
17082468
33.
34.

Mapping genetic modulators of amyloid plaque deposition in TgCRND8 transgenic mice.

Sebastiani G, Krzywkowski P, Dudal S, Yu M, Paquette J, Malo D, Gervais F, Tremblay P.

Hum Mol Genet. 2006 Aug 1;15(15):2313-23. Epub 2006 Jun 19.

PMID:
16785251
35.

Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis.

Gervais F, Paquette J, Morissette C, Krzywkowski P, Yu M, Azzi M, Lacombe D, Kong X, Aman A, Laurin J, Szarek WA, Tremblay P.

Neurobiol Aging. 2007 Apr;28(4):537-47. Epub 2006 May 3.

PMID:
16675063
36.
37.

The C3a receptor antagonist SB 290157 has agonist activity.

Mathieu MC, Sawyer N, Greig GM, Hamel M, Kargman S, Ducharme Y, Lau CK, Friesen RW, O'Neill GP, Gervais FG, Therien AG.

Immunol Lett. 2005 Sep 15;100(2):139-45. Epub 2005 Mar 25.

PMID:
16154494
38.

The cAMP-specific phosphodiesterase 4B mediates Abeta-induced microglial activation.

Sebastiani G, Morissette C, Lagacé C, Boulé M, Ouellette MJ, McLaughlin RW, Lacombe D, Gervais F, Tremblay P.

Neurobiol Aging. 2006 May;27(5):691-701. Epub 2005 Jul 1.

PMID:
15993984
39.

Identification of a potent and selective synthetic agonist at the CRTH2 receptor.

Gervais FG, Morello JP, Beaulieu C, Sawyer N, Denis D, Greig G, Malebranche AD, O'Neill GP.

Mol Pharmacol. 2005 Jun;67(6):1834-9. Epub 2005 Mar 8.

PMID:
15755909
40.

Differences in the amyloid-beta-induced inflammatory response in microglia from C57BL/6 and A/J strains of mice.

Dudal S, Morissette C, Lacombe D, Tremblay P, Gervais F.

J Neuroimmunol. 2004 Aug;153(1-2):26-35.

PMID:
15265660
41.

Inflammation occurs early during the Abeta deposition process in TgCRND8 mice.

Dudal S, Krzywkowski P, Paquette J, Morissette C, Lacombe D, Tremblay P, Gervais F.

Neurobiol Aging. 2004 Aug;25(7):861-71.

PMID:
15212840
42.

Expression of prostaglandin D synthase and the prostaglandin D2 receptors DP and CRTH2 in human nasal mucosa.

Nantel F, Fong C, Lamontagne S, Wright DH, Giaid A, Desrosiers M, Metters KM, O'Neill GP, Gervais FG.

Prostaglandins Other Lipid Mediat. 2004 Jan;73(1-2):87-101.

PMID:
15165034
43.

Stereoselective interactions of peptide inhibitors with the beta-amyloid peptide.

Chalifour RJ, McLaughlin RW, Lavoie L, Morissette C, Tremblay N, Boulé M, Sarazin P, Stéa D, Lacombe D, Tremblay P, Gervais F.

J Biol Chem. 2003 Sep 12;278(37):34874-81. Epub 2003 Jul 2.

44.

Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2.

Sawyer N, Cauchon E, Chateauneuf A, Cruz RP, Nicholson DW, Metters KM, O'Neill GP, Gervais FG.

Br J Pharmacol. 2002 Dec;137(8):1163-72.

45.

Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi.

Gervais FG, Singaraja R, Xanthoudakis S, Gutekunst CA, Leavitt BR, Metzler M, Hackam AS, Tam J, Vaillancourt JP, Houtzager V, Rasper DM, Roy S, Hayden MR, Nicholson DW.

Nat Cell Biol. 2002 Feb;4(2):95-105.

PMID:
11788820
46.

STK receptor tyrosine kinase regulates susceptibility to infection with Listeria monocytogenes.

Lutz MA, Gervais F, Bernstein A, Hattel AL, Correll PH.

Infect Immun. 2002 Jan;70(1):416-8.

47.

Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD2 receptors CRTH2 and DP.

Gervais FG, Cruz RP, Chateauneuf A, Gale S, Sawyer N, Nantel F, Metters KM, O'neill GP.

J Allergy Clin Immunol. 2001 Dec;108(6):982-8.

PMID:
11742277
48.

Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy.

Gervais F, Chalifour R, Garceau D, Kong X, Laurin J, Mclaughlin R, Morissette C, Paquette J.

Amyloid. 2001 Jul;8 Suppl 1:28-35.

PMID:
11676287
49.

Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695.

Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, Strome R, Zuker N, Loukides J, French J, Turner S, Lozza G, Grilli M, Kunicki S, Morissette C, Paquette J, Gervais F, Bergeron C, Fraser PE, Carlson GA, George-Hyslop PS, Westaway D.

J Biol Chem. 2001 Jun 15;276(24):21562-70. Epub 2001 Mar 15.

50.

Huntingtin interacting protein 1 induces apoptosis via a novel caspase-dependent death effector domain.

Hackam AS, Yassa AS, Singaraja R, Metzler M, Gutekunst CA, Gan L, Warby S, Wellington CL, Vaillancourt J, Chen N, Gervais FG, Raymond L, Nicholson DW, Hayden MR.

J Biol Chem. 2000 Dec 29;275(52):41299-308.

Supplemental Content

Loading ...
Support Center